Software Effective Solutions Corp. (SFWJ) Strengthens Position with Growing Number of Cannabis Studies
- A recent study shows that medical cannabis treatment may be associated with improvements in health-related quality of life
- Study data indicated that chronic noncancer pain was the most common indication for treatment, followed by cancer pain, insomnia and anxiety
- MedCana is building the technology, laboratories, growing facilities and scientific teams needed to provide premium pharmaceutical-grade cannabis extracts to the world
Cannabis, long shrouded in controversy, is stepping into the limelight of scientific inquiry, revealing a complex tapestry of potential benefits. Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ), a global infrastructure and holding company in the cannabis industry, is paying close attention to growing data showing the power of the natural substance.
One recent study, conducted by postdoctoral research fellow Thomas Arkell, a PhD at Swinburne University of Technology in Melbourne, Australia, suggests that medical cannabis treatment may be associated with improvements in health-related quality of life among patients with a range of health conditions (https://nnw.fm/wK9oF ). The results of the study were published earlier this year by JAMA Network Open.
“The use of cannabis as a medicine is becoming increasingly prevalent,” the report stated. “Given the diverse range of conditions being treated with medical cannabis, as well as the vast array of products and dose forms available, clinical evidence incorporating patient-reported outcomes may help determine safety and efficacy.” According to the report, this case series study was conducted at a network of specialist medical clinics and included patients who received treatment for any indication between December 2018 and May 2022.
Results of the study, which included 3,148 patients, were noteworthy. Study data indicated that chronic noncancer pain was the most common indication for treatment, followed by cancer pain, insomnia and anxiety. “After commencing treatment with medical cannabis, patients reported significant improvements relative to baseline on all eight domains of the SF-36 (the 36-item short form health survey questionnaire), and these improvements were mostly sustained over time,” JAMA reported. After controlling for potential confounders in a regression model, treatment with medical cannabis indicated marked improvement.
This is just one of innumerable studies focused on cannabis. Recently, NORML, a nonprofit organization that represents the interests of the tens of millions of Americans who use marijuana responsibly, reported that there are more than 36,000 peer-reviewed papers in the scientific literature referencing the cannabis plant and its cannabinoids, according to a keyword search on the search engine PubMed Central, the U.S. government repository for peer-reviewed scientific research (https://nnw.fm/juH28 ).
“In recent years, this volume of research has grown exponentially, with more than 20,000 papers published just in the past decade,” the report noted. “Much of this more recent research has been dedicated to exploring and verifying cannabis’ therapeutic activities in various patient populations – including in FDA-approved gold-standard clinical trials. A summary of this clinical trial data concluded: ‘Evidence is accumulating that cannabinoids may be useful medicine for certain indications. . . . The classification of marijuana as a Schedule I drug as well as the continuing controversy as to whether or not cannabis is of medical value are obstacles to medical progress in this area. Based on evidence currently available, the Schedule I classification is not tenable; it is not accurate that cannabis has no medical value, or that information on safety is lacking.’”
This is positive news for MedCana, which has five companies focused on pharmaceutical cannabis production, as well a software company focused on managing processes for plant-to-patient operations. In addition, the company recently rounded out its portfolio of holdings with the acquisition of an irrigation and greenhouse technology company.
MedCana’s focus is on developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. MedCana is building the technology, laboratories, growing facilities and scientific teams needed to provide premium pharmaceutical-grade cannabis extracts to the world.
For more information, visit the company’s website at www.MedCana.net.
NOTE TO INVESTORS: The latest news and updates relating to SFWJ are available in the company’s newsroom at https://nnw.fm/SFWJ
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- A recent study shows that medical cannabis treatment may be associated with improvements in health-related quality of life
- Study data indicated that chronic noncancer pain was the most common indication for treatment, followed by cancer pain, insomnia and anxiety
- MedCana is building the technology, laboratories, growing facilities and scientific teams needed to provide premium pharmaceutical-grade cannabis extracts to the world
Cannabis, long shrouded in controversy, is stepping into the limelight of scientific inquiry, revealing a complex tapestry of potential benefits. Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ), a global infrastructure and holding company in the cannabis industry, is paying close attention to growing data showing the power of the natural substance.
One recent study, conducted by postdoctoral research fellow Thomas Arkell, a PhD at Swinburne University of Technology in Melbourne, Australia, suggests that medical cannabis treatment may be associated with improvements in health-related quality of life among patients with a range of health conditions (https://nnw.fm/wK9oF ). The results of the study were published earlier this year by JAMA Network Open.
“The use of cannabis as a medicine is becoming increasingly prevalent,” the report stated. “Given the diverse range of conditions being treated with medical cannabis, as well as the vast array of products and dose forms available, clinical evidence incorporating patient-reported outcomes may help determine safety and efficacy.” According to the report, this case series study was conducted at a network of specialist medical clinics and included patients who received treatment for any indication between December 2018 and May 2022.
Results of the study, which included 3,148 patients, were noteworthy. Study data indicated that chronic noncancer pain was the most common indication for treatment, followed by cancer pain, insomnia and anxiety. “After commencing treatment with medical cannabis, patients reported significant improvements relative to baseline on all eight domains of the SF-36 (the 36-item short form health survey questionnaire), and these improvements were mostly sustained over time,” JAMA reported. After controlling for potential confounders in a regression model, treatment with medical cannabis indicated marked improvement.
This is just one of innumerable studies focused on cannabis. Recently, NORML, a nonprofit organization that represents the interests of the tens of millions of Americans who use marijuana responsibly, reported that there are more than 36,000 peer-reviewed papers in the scientific literature referencing the cannabis plant and its cannabinoids, according to a keyword search on the search engine PubMed Central, the U.S. government repository for peer-reviewed scientific research (https://nnw.fm/juH28 ).
“In recent years, this volume of research has grown exponentially, with more than 20,000 papers published just in the past decade,” the report noted. “Much of this more recent research has been dedicated to exploring and verifying cannabis’ therapeutic activities in various patient populations – including in FDA-approved gold-standard clinical trials. A summary of this clinical trial data concluded: ‘Evidence is accumulating that cannabinoids may be useful medicine for certain indications. . . . The classification of marijuana as a Schedule I drug as well as the continuing controversy as to whether or not cannabis is of medical value are obstacles to medical progress in this area. Based on evidence currently available, the Schedule I classification is not tenable; it is not accurate that cannabis has no medical value, or that information on safety is lacking.’”
This is positive news for MedCana, which has five companies focused on pharmaceutical cannabis production, as well a software company focused on managing processes for plant-to-patient operations. In addition, the company recently rounded out its portfolio of holdings with the acquisition of an irrigation and greenhouse technology company.
MedCana’s focus is on developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. MedCana is building the technology, laboratories, growing facilities and scientific teams needed to provide premium pharmaceutical-grade cannabis extracts to the world.
For more information, visit the company’s website at www.MedCana.net.
NOTE TO INVESTORS: The latest news and updates relating to SFWJ are available in the company’s newsroom at https://nnw.fm/SFWJ
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
